Version 1
: Received: 16 October 2019 / Approved: 18 October 2019 / Online: 18 October 2019 (07:18:47 CEST)
How to cite:
Sonkin, D.; Simon, R. Early Detection is as Important as Imatinib in CML Treatment Success. Preprints2019, 2019100207. https://doi.org/10.20944/preprints201910.0207.v1
Sonkin, D.; Simon, R. Early Detection is as Important as Imatinib in CML Treatment Success. Preprints 2019, 2019100207. https://doi.org/10.20944/preprints201910.0207.v1
Sonkin, D.; Simon, R. Early Detection is as Important as Imatinib in CML Treatment Success. Preprints2019, 2019100207. https://doi.org/10.20944/preprints201910.0207.v1
APA Style
Sonkin, D., & Simon, R. (2019). Early Detection is as Important as Imatinib in CML Treatment Success. Preprints. https://doi.org/10.20944/preprints201910.0207.v1
Chicago/Turabian Style
Sonkin, D. and Richard Simon. 2019 "Early Detection is as Important as Imatinib in CML Treatment Success" Preprints. https://doi.org/10.20944/preprints201910.0207.v1
Abstract
Chronic myelogenous leukemia (CML) was the first malignancy for which clinical outcome was drastically improved by kinase inhibitor therapy. Kinase inhibitors targeting other well-known oncogenes have been introduced into clinical practice, but none have shown the same magnitude of clinical benefit as ABL1 inhibition in CML. We argue that early detection is an underappreciated, but critically important factor in success of ABL1 inhibitors in treatment of CML. We show that CML provides a window into how many types of cancer may look and behave at an early stage, prior to diagnosis and the development of additional genomic alterations. The remarkable clinical benefits of ABL1 inhibition is likely due to early detection of CML at a stage in which the tumor is driven by single oncogenic alteration which can be successfully controlled by the inhibitor. Thinking of CML as a prototype for effective systemic treatment based on early cancer detection may help to develop strategies for improving treatment for other types of cancer.
Keywords
CML; Imatinib; early detection; cancer; tumor progression; oncology; Gleevec; Glivec
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
